Structural analysis of the biopharmaceutical innovation network in Ile-de-France

Analyse structurelle du réseau d’innovation biopharmaceutique en Ile-de-France

Sofiane Tahi (), Khaled Belghoul, Vanessa Casadella () and Wafa Khlif
Additional contact information
Sofiane Tahi: LEFMI - Laboratoire d’Économie, Finance, Management et Innovation - UR UPJV 4286 - UPJV - Université de Picardie Jules Verne
Khaled Belghoul: LEFMI - Laboratoire d’Économie, Finance, Management et Innovation - UR UPJV 4286 - UPJV - Université de Picardie Jules Verne
Vanessa Casadella: LEFMI - Laboratoire d’Économie, Finance, Management et Innovation - UR UPJV 4286 - UPJV - Université de Picardie Jules Verne
Wafa Khlif: TBS - Toulouse Business School

Post-Print from HAL

Abstract: Companies are constantly developing into networks. This trend is particularly prevalent in innovation and R&D-based sectors. In these science-based sectors, companies have profoundly modified their organizational structures by building and/or inserting themselves into complex networks. In this article, we will try to understand and analyze the structuring of the alliance networks within the biopharmaceutical industry of one of the most dynamic regions in this field, the Ile-de-France region. It will also involve mapping the nature of these alliances, through the study of regional collaborative projects, and studying the interactions between the different players within its networks. We will establish a strong correlation between the performance of a network, on the one hand, and the structuring and interaction of its actors, on the other. To do this, we carried out an empirical study which allowed us to identify the role of major players through collaborative regional R&D projects in Ile-de-France. This approach makes it possible to identify the positions of the players within the network and to analyze the interactions at stake between these different players. We observe this evolution over a period of eleven years, from 2005 to 2016. The results of this empirical study made it possible to establish the architecture of the Ile-de-France network over a period of 11 years while analyzing the correlation between the centrality of the main players (big pharma and public organizations) and their capacity for innovation within the network itself.

Date: 2021-04-27
References: Add references at CitEc
Citations:

Published in Gestion 2000, 2021, 38 (1), pp.17-29. ⟨10.3917/g2000.381.0017⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03821624

DOI: 10.3917/g2000.381.0017

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().